Approaches to management of cardiovascular morbidity in adult cancer patients - cross-sectional survey among cardio-oncology experts.
Cardio-oncology
Expert-based opinion
Management
Prevention
Journal
Cardio-oncology (London, England)
ISSN: 2057-3804
Titre abrégé: Cardiooncology
Pays: England
ID NLM: 101689938
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
05
2020
accepted:
19
08
2020
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
5
9
2020
Statut:
epublish
Résumé
In cardio-oncology, a range of clinical dilemmas can be identified where high-quality evidence for management is still lacking. The aim of this project was to study clinical practices and expert approaches to several clinical cardio-oncological dilemmas regarding prediction, prevention and treatment of cardiovascular disease in adult cancer patients. A cross-sectional online survey was sent out to internationally renowned experts in the field of cardio-oncology. Participants were selected based on being first or last authors of papers in the field of cardio-oncology, or principal investigators to trials in this field. Topics discussed include, among others, the use of biomarkers for subclinical cardiovascular toxicity, approaches towards primary prevention and follow-up with medication and life-style recommendations, and management of fluoropyrimidine-vasospasm, QTc-prolongation and asymptomatic declines in left ventricular ejection fraction. The answers provided in this survey have shed light on expert-based practices in cardio-oncologic dilemmas. Attitudes towards, as well as discrepancies in those dilemmas are presented. Existing discrepancies clearly indicate the need for generation of high-quality data that allows for more evidence-based recommendations in the future.
Sections du résumé
BACKGROUND
BACKGROUND
In cardio-oncology, a range of clinical dilemmas can be identified where high-quality evidence for management is still lacking. The aim of this project was to study clinical practices and expert approaches to several clinical cardio-oncological dilemmas regarding prediction, prevention and treatment of cardiovascular disease in adult cancer patients.
METHODS
METHODS
A cross-sectional online survey was sent out to internationally renowned experts in the field of cardio-oncology. Participants were selected based on being first or last authors of papers in the field of cardio-oncology, or principal investigators to trials in this field.
RESULTS
RESULTS
Topics discussed include, among others, the use of biomarkers for subclinical cardiovascular toxicity, approaches towards primary prevention and follow-up with medication and life-style recommendations, and management of fluoropyrimidine-vasospasm, QTc-prolongation and asymptomatic declines in left ventricular ejection fraction.
CONCLUSION
CONCLUSIONS
The answers provided in this survey have shed light on expert-based practices in cardio-oncologic dilemmas. Attitudes towards, as well as discrepancies in those dilemmas are presented. Existing discrepancies clearly indicate the need for generation of high-quality data that allows for more evidence-based recommendations in the future.
Identifiants
pubmed: 32884837
doi: 10.1186/s40959-020-00070-y
pii: 70
pmc: PMC7460793
doi:
Types de publication
Journal Article
Langues
eng
Pagination
16Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests
Références
J Am Coll Cardiol. 2011 Aug 23;58(9):988-9
pubmed: 21851890
Cardiovasc Toxicol. 2017 Apr;17(2):130-139
pubmed: 27003392
Mayo Clin Proc. 2014 Sep;89(9):1287-306
pubmed: 25192616
Can J Cardiol. 2016 Jul;32(7):831-41
pubmed: 27343741
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
JAMA Oncol. 2018 Nov 1;4(11):1553-1568
pubmed: 29860482
Med Teach. 2016;38(3):217-28
pubmed: 26648511
J Clin Oncol. 2017 Mar 10;35(8):893-911
pubmed: 27918725
BMC Med Res Methodol. 2015 Apr 09;15:32
pubmed: 25888346
Ann Oncol. 2020 Feb;31(2):171-190
pubmed: 31959335
Circulation. 2018 Feb 20;137(8):e30-e66
pubmed: 29437116
PLoS One. 2011 Feb 23;6(2):e16942
pubmed: 21373197
J Am Heart Assoc. 2014 Feb 28;3(1):e000472
pubmed: 24584736
JAMA Oncol. 2016 Aug 1;2(8):1030-7
pubmed: 27348762
Oncologist. 2019 Feb;24(2):273-284
pubmed: 30257888
Am J Cardiol. 2018 Dec 1;122(11):1959-1964
pubmed: 30292333
Endocr Relat Cancer. 2018 Jan;25(1):11-19
pubmed: 29018055
J Am Coll Cardiol. 2013 Jun 11;61(23):2355-62
pubmed: 23583763
J Clin Oncol. 2017 May 20;35(15):1641-1649
pubmed: 28319436
N Engl J Med. 2018 Dec 20;379(25):2438-2450
pubmed: 30575480
Int J Cardiol. 2019 Jun 15;285:47-52
pubmed: 30905520
Breast Cancer Res Treat. 2018 May;169(1):93-103
pubmed: 29349712
Can Fam Physician. 2008 Oct;54(10):1424-30
pubmed: 18854472
Curr Oncol Rep. 2019 Apr 6;21(6):47
pubmed: 30955114
Ann Oncol. 2007 Mar;18(3):581-92
pubmed: 17287242
Eur J Cancer. 2018 May;94:126-137
pubmed: 29567630
Lancet Oncol. 2007 Sep;8(9):784-96
pubmed: 17714993